tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Fosun Pharma Proposes 2025 H Share RSU Scheme to Boost Long-Term Growth

Story Highlights
Fosun Pharma Proposes 2025 H Share RSU Scheme to Boost Long-Term Growth

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an update.

Shanghai Fosun Pharmaceutical has announced the proposed adoption of the 2025 H Share RSU Scheme, aimed at enhancing corporate governance and establishing a long-term incentive mechanism. The scheme, which requires shareholder approval, includes a first grant of 10,696,400 RSUs to 201 eligible employees, aligning the interests of shareholders and key personnel to drive the company’s long-term development.

The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on developing, manufacturing, and selling pharmaceutical products and medical devices, with a market focus on both domestic and international sectors.

YTD Price Performance: 49.18%

Average Trading Volume: 10,777,457

Technical Sentiment Signal: Hold

Current Market Cap: HK$76.06B

See more insights into 2196 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1